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Purpose: The aim of this study was to evaluate the effect of desmopressin combined 
with anticholinergics on daytime frequency and urgency in female patients with over-
active bladder (OAB).
Materials and Methods: We included 68 female patients with OAB. Patients were ran-
domly assigned to receive 5 mg of solifenacin (group I) or 5 mg of solifenacin and 0.2 
mg of desmopressin (group II) for 2 weeks. A pre/post-treatment 3-day voiding diary 
and the Urinary Distress Inventory (UDI-6) and Incontinence Impact Questionnaire 
(IIQ-7) were used to assess changes in voiding symptoms and quality of life (QoL); re-
sults were compared between the two groups.
Results: Groups I and II included 31 and 37 patients, respectively. Time to first void 
was 12 min later in group II (105 min vs. 117 min), but this difference was not statisti-
cally significant. However, time to the second and third voids (203 min vs. 255 min, 
312 min vs. 368 min) and the first urgency episode (212 min vs. 255 min) were sig-
nificantly longer in group II. Compared with group I, patients in group II showed sig-
nificant improvement in QoL scores. When improvement after treatment was defined 
as increase in time to first void of greater than 10% after 2 weeks of treatment, desmo-
pressin with anticholinergics was more effective in patients over the age of 65 years 
and with more than 150 ml of voided volume.
Conclusions: Desmopressin combined with anticholinergics was more effective than 
anticholinergics only in the treatment of female patients with OAB.
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Overactive bladder (OAB) is a symptom syndrome that is 
defined as urgency, with or without urge incontinence, usu-
ally with frequency and nocturia, and is known to have a 
significant impact on quality of life (QoL) [1-5]. Traditio-
nally, anticholinergic drugs have been widely used for the 
treatment of OAB. However, their effectiveness is known 
to be 60% to 70% [6]. Additionally, they lack selectivity for 
the bladder, and effects on other organ systems may result 
in side effects, including dry mouth, blurred vision, con-
stipation, and dizziness, which limit their usefulness [7].
　Desmopressin is a synthetic vasopressin analogue with 
a pronounced antidiuretic effect that is used widely for the 
treatment of primary nocturnal enuresis and nocturnal 
polyuria [8,9].
　Several recent clinical trials have reported promising re-
sults showing improvement of symptoms of daytime fre-
quency and urgency in patients with OAB with desmo-
pressin through decreases in renal urine production and 
increases in bladder filling time [10,11]. However, there 
have been no reports concerning the effect of desmopressin 
combined with anticholinergics. Therefore, we performed 
this study to evaluate the effect of desmopressin combined 
with anticholinergics on daytime frequency and urgency in 
female patients with OAB.Korean J Urol 2011;52:396-400
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TABLE 1. Baseline patient characteristics in each group (mean±SD)
 Group  I Group  II p-value
No. of patients 31 37
Age (yr) 56.3±6.7 52.3±8.1 0.107
Time to first void (min)    78±12.3    82±18.7 0.172
Time to first urgency 
episode (min)
 196±32.5  187±27.7 0.182
No. of voids (first 8-hr) 5.1±1.2 4.8±0.8 0.327
No. of urgency episodes 
(first 8-hr) 
2.8±0.4 3.2±0.4 0.572
UDI-6 43.1±22.6 48.7±17.3 0.272
IIQ-7 48.8±26.8 52.3±18.2 0.731
UDI-6: Urogenital Distress Inventory, IIQ-7: Incontinence 
Impact Questionnaire 




FIG. 2. Time to first urgency episode after treatment (
a: p=0.002).
MATERIALS AND METHODS
1. Patients and study design
Between July 2008 and June 2009, patients were recruited 
at one tertiary urologic institution. Eligible patients were 
females 18 years and older with OAB syndrome who had 
at least four voids in the first 8 hours of the day after rising, 
excluding the first morning void.
　Patients with abnormal renal function or serum electro-
lytes, significant pelvic organ prolapse, stress urinary in-
continence, urinary tract infection, significant postvoid re-
sidual (＞150 ml), or a history of medication for treatment 
of OAB within 30 days were excluded.
　The study was conducted in accordance with ethical prin-
ciples that have their origins in the Declaration of Helsinki, 
and written informed consent was obtained from all pa-
tients before recruitment into the study.
　Patients were randomly assigned to receive 5 mg of sol-
ifenacin (group I) or 5 mg of solifenacin and 0.2 mg of desmo-
pressin (group II) for 2 weeks. Patients were instructed to 
take the tablets after the first morning void. 
2. Efficacy assessments
The primary efficacy end point was evaluation of the effec-
tiveness of desmopressin in increasing the time to each of 
the first OAB symptom episodes (frequency and urgency). 
The secondary efficacy end points were evaluation of the 
effectiveness of desmopressin on QoL, in decreasing the 
average number of OAB symptoms (frequency and ur-
gency) during the first 8 hours of the day following treat-
ment, and outcome predictors of desmopressin with anti-
cholinergics. Efficacy measures included 3-day voiding di-
ary variables, the Urogenital Distress Inventory (UDI-6), 
and the Incontinence Impact Questionnaire (IIQ-7), which 
were completed by patients at baseline and at week 2 and 
were assessed as the change from baseline. Safety assess-
ments including body weight, serum sodium monitoring, 
and adverse event reports were recorded at baseline and 
week 2. Scores on the UDI-6 and IIQ-7 were calculated on 
a scale from 0 to 100 [12]. A score of 0 indicated that the pa-
tient was not bothered at all by a particular symptom and 
a score of 100 implied the most severe degree of dissatis-
faction with a particular symptom.
3. Statistical analysis
SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA) was used for 
statistical analysis. Student's t-test, Mann-Whitney U 
test, and univariate logistic regression analysis were used 
for statistical assessment of results and a value of p-value
＜0.05 was considered statistically significant.
RESULTS
1. Patients
A total of 84 patients were randomly assigned to 2 groups, 
and 68 (81%) of 84 patients completed the study. Groups 
I and II had 31 and 37 patients, respectively. Mean patient 
age was 54.2±7.3 years and baseline clinical character-
istics were similar among the groups (Table 1).
2. Time to first micturition and urgency episodes
Time to first void was 12 min later in group II (105 min vs. 
117 min) than in group I; however, this difference was not 
statistically significant (Student's t-test, p＞0.05) (Fig. 1). 
However, time to the second and third voids (203 min vs. 
255 min, 312 min vs. 368 min) and time to the first urgency Korean J Urol 2011;52:396-400
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FIG. 3. Numbers of micturition and urgency episodes in each 
group after treatment (
a: p=0.02, 
b: p=0.016).
FIG. 4. Scores on the Urogenital Distress Inventory (UDI-6) and




TABLE 2. Univariate logistic regression analysis of pretreatment parameters with respect to improvement in time to first micturition
in the anticholinergics plus desmopressin group
Parameters
  Improvement in time to 1st micturition (＞10%)
Odds ratio (95% CI) p-value
Age (yr) ＜65 (n=21) 1.00 (reference) 0.048
≥65 (n=16) 1.16 (1.00-1.38)
No. of micturitions (first 8 hr)  1.52 (0.59-3.91) 0.379
No. of urgency episodes (first 8 hr) 1.25 (0.82-1.91) 0.281
Urge incontinence − (n=25) 1.00 (reference) 0.091
＋  (n=12) 2.12 (0.88-5.07)
Voided volume ＜150 ml (n=15) 1.00 (reference) 0.001
≥150 ml (n=22) 1.34 (1.13-1.59)
CI: confidence interval
episode (212 min vs. 255 min) were significantly longer in 
group II (Student's t-test, p＜0.05) (Fig. 1, 2).
3. Changes in the numbers of micturition and urgency epi-
sodes during the first 8 hours of the day following treat-
ment and impact on QoL
Significant decreases were observed in the numbers of 
voids (4.5 vs. 3.2) and urgency episodes (2.6 vs. 1.7) during 
the first 8 hours following treatment in group II compared 
with group I (Mann-Whitney U test, p＜0.05) (Fig. 3). Com-
pared with group I, patients in group II showed significant 
improvement in QoL scores as measured by the UDI-6 and 
IIQ-7 (Student's t-test, p＜0.05) (Fig. 4).
4. Outcome predictors of desmopressin with anticholi-
nergics
When improvement after treatment was defined as an in-
crease in time to first void of greater than 10% after 2 weeks 
of treatment, desmopressin with anticholinergics was 
more effective in patients over the age of 65 years (odds ra-
tio [OR]=1.2, 95% confidence interval [CI]: 1.00-1.16, p＜ 
0.05) (Table 2) and with more than 150 ml of voided volume 
(OR=1.3, 95% CI: 1.13-1.59, p＜0.01) (Table 2) in the uni-
variate regression analysis for determination of predictive 
factors influencing improvement.
5. Adverse events
No significant changes in serum sodium or body weight were 
observed. Although adverse events occurred in a total of 2 
(5.4%) patients, symptoms were generally mild (headache 
and diarrhea).
DISCUSSION
OAB is a symptom syndrome consisting of urgency, with 
or without urgency incontinence, usually with frequency 
and nocturia [1], and is a common and distressing condition 
known to have an adverse effect on QoL [2-5]. First-line 
therapy for OAB includes conservative treatment in the 
form of lifestyle intervention, pelvic floor exercises, and 
bladder training. These offer better results when combined 
with anticholinergics, which are the first-line medical ther-
apy for OAB. However, anticholinergic medication is asso-
ciated with typical side effects, including dry mouth, con-
stipation, and blurred vision. Compliance with anticholi-
nergic medication is also a significant problem. In a ques-
tionnaire follow-up study of women with OAB, only 5.5% 
were cured of their OAB symptoms and only 18.2% of wom-Korean J Urol 2011;52:396-400
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en continued drug therapy for longer than 6 months [7]. 
　For OAB patients who are refractory to anticholinergics, 
modalities such as botulinum toxin injection, neuromodu-
lation, and various surgical interventions can be attempted. 
However, these also have side effects and limitations and 
are not curative. Therefore, discovery of alternative modal-
ities of medical treatment for OAB, which could delay any 
invasive treatments, is crucial.
　Desmopressin (1-desamino-8-D-arginine vasopressin) 
is a synthetic nonapeptide analogue of antidiuretic hor-
mone that affects renal water reabsorption, leading to de-
creased urine production. To date, desmopressin has been 
used in the treatment of disorders such as diabetes in-
sipidus, primary nocturnal enuresis, and nocturia with a 
polyuric background. 
　Well-controlled trials have been performed to evaluate 
the safety, efficacy, and tolerability of desmopressin in the 
treatment of patients with nocturia [13-16]. Duration of the 
period from bedtime until the first nocturnal void (first 
sleep period) is one of the frequently used efficacy end 
points in clinical trials for evaluation of the efficacy of des-
mopressin in patients with nocturia; findings from pre-
viously reported studies have shown an increase in the first 
sleep period of 1.5 to 2.2 hours [17].
　Some recent studies have reported the efficacy of desmo-
pressin in patients with OAB [10,11]. The rationale for use 
of desmopressin in the treatment of OAB patients is that 
through a decrease in urine production, desmopressin will 
increase the time taken to reach functional bladder ca-
pacity between daytime voids, thereby reducing frequency 
and urgency and benefiting adults suffering from OAB. 
This is very similar to the rationale for use of desmopressin 
in nocturia patients; therefore, we used the time to the first 
OAB symptom episode (micturition and urgency) as the 
primary end point, because in previous desmopressin tri-
als, the concept of time to the first nocturnal void was used 
and this was increased by use of desmopressin, resulting 
in a greater number of hours of undisturbed sleep [14,15]. 
　Robinson et al administered 40 μg intranasal desmo-
pressin to 64 women with urinary incontinence lasting over 
10 days [11]. Results showed that patients taking desmo-
pressin had a significantly higher mean incidence of peri-
ods with no leakage during the first 4 and 8 hours after tak-
ing desmopressin. This study was the first to explore the 
concept of antidiuresis as a strategy for management of 
daytime OAB symptoms in women and the results were 
very encouraging; however, it did not look at the effect on 
other OAB symptoms, such as frequency and urgency.
　Recently, in a double-blind placebo-controlled trial that 
evaluated the efficacy of desmopressin in the treatment of 
female patients with OAB, desmopressin induced a sig-
nificant increase in the time to the first urgency episode, 
with a significant reduction in the mean numbers of ur-
gency episodes, compared to placebo, and subjective im-
provement was observed in frequency and urgency as well 
as overall QoL [10].
　Currently, anticholinergics are the primary treatment 
for OAB; therefore, unlike previous studies [10,11] con-
cerning the efficacy of desmopressin in patients with OAB, 
which compared the desmopressin group and the placebo 
group, our study was designed to address the issue of phar-
macological antidiuresis in OAB patients who take anti-
cholinergic medication.
　Like the previous studies, we analyzed the changes in 
OAB symptoms during the first 8 hours of the day following 
medication because it is known that desmopressin is most 
effective during this period.
　In our study, desmopressin did not induce a significant 
increase in the time to the first frequency episode; however, 
the time to the first urgency episode increased and the num-
bers of frequency and urgency episodes showed a significant 
decrease in the desmopressin with anticholinergics group. 
In addition, QoL as measured by the UDI-6 and IIQ-7 
showed significant improvement in the desmopressin with 
anticholinergics group. These results are similar to those 
of the previous study [10]. In the future, antidiuresis using 
desmopressin could have potential for use in the treatment 
of OAB.
　The effects of desmopressin in our patients were prob-
ably due to the decreased urine volume in the daytime. 
However, we did not analyze the changes in urine volume 
because measurement of urinary output was incomplete in 
most of our patients, and this may be one drawback of the 
study. In addition, the 2-week period of our study was too 
short to conclude that combined therapy is more effective 
than anticholinergics alone on a long-term basis, because 
the effect of anticholinergics could be gradually increased 
up to 2 to 3 months. Therefore, larger long-term studies will 
need to be conducted to prove the concept that reduction 
in urine volume production helps in OAB patients and to 
determine the long-term effect of combined therapy.
　There have been no reports concerning the predictive fac-
tors for the effect of desmopressin with anticholinergics in 
OAB patients. Therefore, we performed subanalysis of the 
desmopressin with anticholinergics group to evaluate the 
outcome predictors of desmopressin in OAB patients. Age 
(＞65 years) and voided volume (＞150 ml) showed a sig-
nificant association with improvement of OAB symptoms 
after desmopressin medication. 
　However, these results had some drawbacks, because it 
is not known how many increases in time to first void is 
needed to improve QoL, and the number of patients in the 
desmopressin with anticholinergics group was small. 
Therefore, the outcome predictors of desmopressin with 
anticholinergics in OAB patients should be explored fur-
ther in a larger confirmatory trial.
　Hyponatremia is the only serious potential adverse 
event associated with the use of desmopressin [18-20]. In 
the present study, desmopressin was well tolerated by the 
majority of patients. No significant hyponatremia was re-
ported in any patient. However, significant hyponatremia 
occurred in 4% to 6% of patients in the published trials 
[21,22], particularly in patients over the age of 65 years. 
Therefore, precautions should be taken in older patients, Korean J Urol 2011;52:396-400
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including close monitoring of prodromal symptoms, such 
as headache and weight increase, and avoidance of ex-
cessive fluid intake.
CONCLUSIONS
Desmopressin combined with anticholinergics was more 
effective than anticholinergics alone in the treatment of fe-
male patients with OAB. Therefore, desmopressin com-
bined with anticholinergics could be considered as a novel, 
feasible method for relief of symptoms in female patients 
with OAB, and larger long-term studies will need to be con-
ducted of the use of desmopressin in patients with OAB on 
a long-term basis.
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